ABSTRACT
Thrombolytic therapy has become the standard of care for the treatment of numerous thrombotic
diseases. The basic pharmacological work to identify effective agents relies heavily on preclinical
experimental models. Treatment with thrombolytic agents induces an increased bleeding risk;
therefore, the safety profile of new treatment strategies requires in-depth investigation in
preclinical in vivo models. Many experimental models have been developed to investigate the
mechanisms of thrombosis and to optimize antithrombotic and thrombolytic therapy.